Muhammad A. Shipa

250 Euston Road
London, ENG NW12PG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis.

Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis.

Journal: Pediatric rheumatology online journal

Published: October 20, 2025

Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE.

Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE.

Journal: The Lancet. Rheumatology

Published: July 01, 2025

IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus.

IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus.

Journal: Cell reports. Medicine

Published: January 08, 2025

SLE is not a one-size-fits-all disease.

SLE is not a one-size-fits-all disease.

Journal: The Journal of experimental medicine

Published: April 25, 2023

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.

Journal: The Lancet. Rheumatology

Published: February 09, 2023

Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?

Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?

Journal: Modern rheumatology

Published: June 01, 2022

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis.

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis.

Journal: Rheumatology (Oxford, England)

Published: February 24, 2022

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.

Journal: Annals of internal medicine

Published: October 26, 2021

An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.

An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.

Journal: Rheumatology (Oxford, England)

Published: August 02, 2020

Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.

Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.

Journal: Annals of the rheumatic diseases

Published: April 23, 2020

CNS Vasculitis in Anti-Synthetase Syndrome.

CNS Vasculitis in Anti-Synthetase Syndrome.

Journal: Mediterranean journal of rheumatology

Published: March 19, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026